Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun An atypical antipsychotic under development for the treatment of schizophrenia and acute mania associated with bipolar disorder.

Etymologies

Sorry, no etymologies found.

Examples

  • The Food and Drug Administration gave final approval to Schering-Plough Corp. 's asenapine, a treatment for both schizophrenia and bipolar disorder in adults.

    FDA OKs Schering-Plough Drug for Schizophrenia, Bipolar

  • In addition to the two companies 'currently marketed neuroscience products, Schering-Plough brings several promising late-stage candidates, including SAPHRIS (asenapine), an antipsychotic drug for the treatment of schizophrenia and bipolar disorder, and BRIDION (suggamadex), a novel anesthesia reversal agent.

    Merck, Schering-Plough Statement

  • "We see growth of the CNS central nervous system division driven by Lyrica, Geodon, as well as Indiplon, vareniclin, and asenapine."

    Pfizer Seen With Two Drug Approvals In May

  • Haloperidol also had the highest number of significant differences in head-to-head comparisons, coming out better than Otsuka Pharmaceutical's Abilify, known generically as aripiprazole; carbamazepine, sold as Carbatrol by Shire and Tegretol by Novartis; valproate, sold by Abbott Laboratories as Depakine and Sanofi-Aventis as Epilim; Lundbeck's and Merck's asenapine.

    Reuters: Press Release

  • SAPHRIS (asenapine), Merck's sublingual tablet for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder, was approved for use in the United States during the third quarter of 2009 and a full launch is under way.

    THE MEDICAL NEWS

  • The application for asenapine is also under review in the EU.

    THE MEDICAL NEWS

  • SAPHRIS (asenapine), Merck's sublingual tablet for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder, was approved for use in the United States during the third quarter of 2009 and a full launch is under way.

    WebWire | Recent Headlines

  • SAPHRIS (asenapine), Merck's sublingual tablet for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder, was approved for use in the United States during the third quarter of 2009 and a full launch is under way.

    THE MEDICAL NEWS

  • The application for asenapine is also under review in the EU.

    WebWire | Recent Headlines

  • The application for asenapine is also under review in the EU.

    THE MEDICAL NEWS

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.